Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.69 |
| ▸ | CA12 | O43570 | 1/20 | 0.69 |
| ▸ | CA1 | P00915 | 1/20 | 0.69 |
| ▸ | CA2 | P00918 | 1/20 | 0.69 |
| ▸ | CA3 | P07451 | 1/20 | 0.69 |
| ▸ | CA4 | P22748 | 1/20 | 0.69 |
| ▸ | CA6 | P23280 | 1/20 | 0.69 |
| ▸ | CA5A | P35218 | 1/20 | 0.69 |
| ▸ | CA7 | P43166 | 1/20 | 0.69 |
| ▸ | CA9 | Q16790 | 1/20 | 0.69 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.69 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.69 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.69 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3789746 | 1.00 | LMNA (0.69) | LMNACA12CA1CA2CA3 | |
| SCHEMBL3789749 | 1.00 | LMNA (0.69) | LMNACA12CA1CA2CA3 | |
| SCHEMBL15723483 | 0.88 | LMNA (0.56) | LMNACA12CA1CA2CA3 | |
| SCHEMBL21313417 | 0.87 | LMNA (0.69) | LMNACA12CA1CA2CA3 | |
| SCHEMBL1878246 | 0.87 | LMNA (0.69) | LMNACA12CA1CA2CA3 | |
| SCHEMBL8353244 | 0.87 | LMNA (0.69) | LMNACA12CA1CA2CA3 | |
| SCHEMBL13911898 | 0.86 | LMNA (0.71) | LMNACA12CA1CA2CA3 | |
| SCHEMBL4445759 | 0.83 | LMNA (0.63) | LMNACA12CA1CA2CA3 | |
| SCHEMBL14610554 | 0.82 | LMNA (0.50) | LMNACA12CA1CA2CA3 | |
| SCHEMBL5101967 | 0.82 | LMNA (0.50) | LMNACA12CA1CA2CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115260075-A | Method for preparing levetiracetam | 浙江华海药业股份有限公司 | 2022-11-01 | — | — | CN | claimed |
| CN-114409586-A | Preparation method of levetiracetam | 山东诚汇双达药业有限公司 | 2022-04-29 | — | — | CN | claimed |
| WO-2024206349-A1 | PROCESS FOR THE PRODUCTION OF LEVETIRACETAM | SUZHOU BRIGHTHOPE PHARMATECH CO., LTD (CN) | 2024-10-03 | — | — | WO | disclosed |
| CN-110799494-B | Method for preparing levetiracetam without solvent | 浙江华海药业股份有限公司 | 2023-06-06 | — | — | CN | disclosed |
| CN-110799495-B | Synthesis method of levetiracetam | 浙江华海药业股份有限公司 | 2022-12-13 | — | — | CN | disclosed |
| CN-108707099-B | Preparation method of levetiracetam intermediate | 浙江华海药业股份有限公司 | 2022-12-13 | — | — | CN | disclosed |
| CN-115260075-A | Method for preparing levetiracetam | 浙江华海药业股份有限公司 | 2022-11-01 | — | — | CN | disclosed |
| US-20220162165-A1 | PREPARATION METHOD FOR LEVETIRACETAM INTERMEDIATE | ZHEJIANG HUAHAI TIANCHENG PHARMACEUTICAL CO., LTD (CN) | 2022-05-26 | — | — | US | disclosed |
| CN-114409586-A | Preparation method of levetiracetam | 山东诚汇双达药业有限公司 | 2022-04-29 | — | — | CN | disclosed |
| WO-2020216146-A1 | PREPARATION METHOD FOR LEVETIRACETAM INTERMEDIATE | 浙江华海药业股份有限公司 | 2020-10-29 | — | — | WO | disclosed |
| US-8338621-B2 | Process for the preparation of 2-oxo-1-pyrrolidine derivatives | UCB S.A. (BE) | 2012-12-25 | — | — | US | disclosed |
| WO-2008077035-A2 | PROCESSES FOR THE PREPARATION OF LEVETIRACETAM | DR. REDDY'S LABORATORIES LTD. (IN) | 2008-06-26 | — | — | WO | disclosed |
| US-20080146819-A1 | Process for Preparing Levetiracetam | RUBAMIN LIMITED (IN) | 2008-06-19 | — | — | US | disclosed |
| US-20080146819-A1 | Process for Preparing Levetiracetam | RUBAMIN LIMITED (IN) | 2008-06-19 | — | — | US | disclosed |
| WO-2008012268-A1 | PROCESS FOR THE PREPARATION OF LEVETIRACETAM | ZACH SYSTEM S.P.A. (IT) | 2008-01-31 | — | — | WO | disclosed |
| US-20080009638-A1 | PROCESS FOR THE PREPARATION OF 2-OXO-1-PYRROLIDINE DERIVATIVES | UCB S.A. (BE) | 2008-01-10 | — | — | US | disclosed |
| EP-1806339-A1 | Process for the preparation of 2-oxo-1-pyrrolidine derivatives | UCB, S.A. (BE) | 2007-07-11 | — | — | EP | disclosed |
| US-20070142647-A1 | Oxopyrrolidine compounds, preparation of said compounds and their use in the manufacturing of levetiracetam and analogues | ATES CELAL | 2007-06-21 | — | — | US | disclosed |
| US-20070142647-A1 | Oxopyrrolidine compounds, preparation of said compounds and their use in the manufacturing of levetiracetam and analogues | ATES CELAL | 2007-06-21 | — | — | US | disclosed |
| WO-2003014080-A2 | OXOPYRROLIDINE COMPOUNDS, PREPARATION OF SAID COMPOUNDS AND THEIR USE IN THE MANUFACTURING OF LEVETIRACETAM AND ANALOGUES | UCB, S.A. (BE) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009638-A1 | PROCESS FOR THE PREPARATION OF 2-OXO-1-PYRROLIDINE DERIVATIVES | CYP2F1, CYP3A5, SULT1E1 | LMNA 4186/4885CA12 3778/4885CA1 2079/4885 |
| US-20080146819-A1 | Process for Preparing Levetiracetam | ADH1C, ADH1A, ADH5 | LMNA 3024/4885CA12 810/4885CA1 124/4885 |
| US-20220162165-A1 | PREPARATION METHOD FOR LEVETIRACETAM INTERMEDIATE | ADRM1, GABRE, EPM2A | LMNA 2136/4885CA12 4446/4885CA1 2825/4885 |
| US-20070142647-A1 | Oxopyrrolidine compounds, preparation of said compounds and their use in the manufacturing of levetiracetam and analogues | CYP2D6, OTC, CYP2B6 | LMNA 2327/4885CA12 2417/4885CA1 1400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.